1. No category

Publikationsliste
Hans von der Maase
1.
von der Maase H & Sveinsson Th: Kombineret stråle- og kemoterapi som postoperativ behandling af
cancer mammae. Ugeskr Læg 140:1676-1678, 1978.
2.
von der Maase H: Strålekombinationer ved kombineret stråle- og kemoterapi af cancer mammae.
Ugeskr Læg.
3.
Sveinsson Th, von der Maase H & Svendsen K: Cancer coli sigmoidei behandlet med kombineret
stråle- og kemoterapi. Ugeskr Læg 140:2368-2369, 1978.
4.
von der Maase H & Sveinsson Th: Stråle- og/eller cytostatisk behandling af kolorektal cancer.
Ugeskr Læg 140:2360-2363, 1978.
5.
Schultz HP, Arends J & Barlebo H et al.: DATECA-projektet. Det danske testiscancerprojekt. Ugeskr
Læg 140:2563-2566, 1978.
6.
Rasmussen SL, von der Maase H & Hansen MR: Værdien af mammografi som rutinemæssig
undersøgelse efter mastektomi. Ugeskr Læg 141:2889-2890, 1979.
7.
von der Maase H: Radio- and chemotherapy follow-up using fine needle biopsies. In: Ultrasonically
guided puncture technique, pp. 109-112. Editors H.H. Holm & J.K. Kristensen, Munksgaard,
København, 1980.
8.
Rørth M, Hansen M, Hansen HH & von der Maase H: Kombinationskemoterapi af dissemineret nonseminomatøs testiscancer. Ugeskr Læg 142:2691-2693, 1980.
9.
Jacobsen GK, Henriksen OB & von der Maase H: Carcinoma in situ of testicular tissue adjacent to
malignant germ cell tumors: A study of 105 cases. Cancer 47:2660-2662, 1981.
10.
Berthelsen, JG, Skakkebæk NE, von der Maase H, Sørensen BL & Mogensen P: Serum
testosterone, LH, and FSH in patients with testicular cancer before and after radio- and
chemotherapy. Br Med J 285:1683-1686, 1982.
11.
von der Maase H, Magnusson K & Sveinsson Th: Combined irradiation and three-drug
chemotherapy in inoperable colorectal carcinoma. Acta Radiol Oncol 21:369-372, 1982.
12.
Schultz HP, Arends J, Barlebo H et al.: The Danish Testicular Carcinoma Study. Danish Medical
Bulletin 30:1-3, 1983.
13.
von der Maase H & Overgaard J: Microcolony survival assay for jejunal crypt cells exposed to
radiation alone and combined with cancer chemotherapeutic agents – methodical problems. Int J
Radiat Biol 43:45-56, 1983.
1
14.
Berthelsen JG, Engelholm SA, von der Maase H & Rørth M: Serum testosterone, LH, and FSH in
patients with testicular cancer before and after radio- and chemotherapy. Scand J Urol Nephrol
17:287-290, 1983.
15.
von der Maase H: Interactions of radiation and 5-fluorouracil, cyclophosphamide or methotrexate in
intestinal crypt cells. Int J Radiat Oncol Biol Phys 10:77-86, 1984.
16.
von der Maase H, Gammelgaard J, Dragsted J & Bording L: Abdominal ultrasonic scanning versus
lymphangiography in testicular cancer. Scand J Urol Nephrol 18:177-179, 1984.
17.
von der Maase H: Interactions of radiation and 5-fluorouracil, cyclophosphamide or methotrexate in
intestinal crypt cells. Br J Cancer 49:779-786, 1984.
18.
von der Maase H: Effect of cancer chemotherapeutic drugs on the radiation-induced skin reactions in
mouse feet. Br J Radiol 57:697-707, 1984.
19.
Jacobsen GK, Barlebo H, Olsen J et al.: Testicular germ cell tumours in Denmark 1976-1980.
Pathology of 1058 consecutive cases. Acta Radiol Oncol 23:239-247, 1984.
20.
Schultz HP, Arends J, Barlebo H et al.: Testicular carcinoma in Denmark 1976-1980. Stage and
selected clinical parameters at presentation. Acta Radiol Oncol 23:255-261, 1984.
21.
von der Maase H, Engelholm SA, Rørth M et al.: Non-seminomatous testicular germ cell tumours in
Denmark 1976-1980. Results of treatment. Acta Radiol Oncol 23:255-261, 1984.
22.
Schultz HP, von der Maase H, Rørth M et al.: Testicular seminoma in Denmark 1976-1980. Results
of treatment. Acta Radiol Oncol 23:263-270, 1984.
23.
Væth M, Schultz HP, von der Maase H et al.: Prognostic factors in carcinoma of the testis. The
Danish Testicular Carcinoma Study Group. Acta Radiol Oncol 23:271-285, 1984.
24.
Nørgaard-Petersen B, Schultz HP, Arends J et al.: Tumour markers in testicular germ cell tumours. A
5-years’ experience from the Danish Testicular Carcinoma Study Group (1976-1980). Acta Radiol
Oncol 23:287-294, 1984.
25.
Rørth M, von der Maase H, Sandberg Nielsen E et al.: Non-seminomatous germ cell testicular
cancer. Preliminary analysis of ongoing trials in DATECA and future aspects. Acta Radiol Oncol
23:295-304, 1984.
26.
Sparsø BH, von der Maase H, Kristensen D et al.: Complications following postoperative combined
radiation and chemotherapy in adenocarcinoma of the rectum and rectosigmoid. A randomized trial
that failed. Cancer 54:2363-2366, 1984.
27.
Schultz HP, Rørth M, von der Maase H, Sandberg E & Pedersen M: The Danish Testicular
Carcinoma Study. Results from recent clinical trials in non-seminomatous tumours. Acta Urol Belg
53:362-376, 1985.
28.
von der Maase H & Overgaard J: Interactions of radiation and cancer chemotherapeutic drugs in a
C3H mouse mammary carcinoma. Acta Radiol Oncol 24:181-187, 1985.
2
29.
von der Maase H, Berthelsen JG, Jacobsen CK et al.: Carcinoma-in-situ of testis eradicated by
chemotherapy. Lancet i:98, 1985.
30.
von der Maase H: Interactions of drugs and radiation in haemopoietic tissue assessed by lethality of
mice after whole-body irradiation. Int J Radiat Biol 48:371-380, 1985.
31.
Overgaard J, von der Maase H & Overgaard M: A randomized study comparing two high-dose per
fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol
Phys 11:1837-1839, 1985.
32.
Rørth M, von der Maase H, Nielsen ES, Schultz H & Pedersen M: Treatment of non-seminomatous
testicular germ cell tumors in Denmark 1979. Prog Clin Biol Res 203:539-551, 1985.
33.
Overgaard J, Overgaard M, Vejby Hansen P & von der Maase H: Some factors of importance in the
radiation treatment of malignant melanoma. Radiother Oncol 5:183-192, 1986.
34.
von der Maase H, Overgaard J & Vaeth M: Effect of cancer chemotherapeutic drugs on radiationinduced lung damage in mice. Radiother Oncol 5:245-257, 1986.
35.
von der Maase H, Giwercman A & Skakkebæk NE: Radiation treatment of carcinoma-in-situ testis.
Lancet i:624-625, 1986.
36.
von der Maase H: Experimental studies on interactions of radiation and cancer chemotherapeutic
drugs in normal tissues and a solid tumour. Radiother Oncol 7:47-68, 1986.
37.
Andersson M, Daugaard S, von der Maase H & Mouridsen HT: Doxorubicin versus Mitomycin C
versus Doxorubicin plus Mitomycin C in advanced breast cancer: A randomized study. Cancer
Treatment Reports 80:1181-1186, 1986.
38.
von der Maase H, Rørth M, Walbom-Jørgensen S et al.: Carcinoma in situ of contralateral testis in
patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J 293:1398-1401,
1986.
39.
Overgaard J, Matsui M, Lindegaard JC et al.: Relationship between tumor growth delay and
modification on local control probability of various treatments given as an adjuvant to irradiation. In:
Use of rodent tumors in experimental cancer therapy. Editor: R.F. Callman, Pergamon Press,
Oxford, pp. 128-132, 1987.
40.
Giwercman A, Berthelsen JG, Müller J, von der Maase H & Skakkebæk NE: Screening for
carcinoma-in-situ of the testis. Int J Androl 10:173-180, 1987.
41.
von der Maase H, Giwercman A, Müller J & Skakkebæk NE: Management of carcinoma-in-situ of the
testis. Int J Androl 10:209-220, 1987.
42.
Rørth M, von der Maase H, Nielsen ES, Pedersen M & Schultz HP: Orchiectomy alone versus
orchiectomy plus radiotherapy in stage I non-seminomatous testicular cancer. A randomized study
by the Danish Testicular Carcinoma Study Group. Int J Androl 10:225-262, 1987.
43.
Daugaard G, von der Maase H, Olsen J, Rørth M & Skakkebæl NE: Carcinoma-in-situ testis in
patients with assumed extragonadal germ cell tumours. Lancet ii: 528-530, 1987.
3
44.
von der Maase H: Experimental studies on interactions of radiation and cancer chemotherapeutic
drugs in normal tissues and a solid tumour (thesis). København, eget forlag, 1987.
45.
Havsteen H, von der Maase H, Strøjer I & Rasmussen F: Cisplatin as a first-line treatment in T2 and
T3 bladder carcinoma. Cancer Treatment Reports 71:1285-1287, 1987.
46.
Nielsen OS, von der Maase H & Overgaard J: Effect of combined 5-fluorouracil and radiation on
murine haematopoietic tissue. Radiother Oncol 13:245-152, 1988.
47.
von der Maase H, Meinecke B & Skakkebæk NE: Residual carcinoma-in-situ of contralateral testis
after chemotherapy. Lancet i:477-478, 1988.
48.
Skakkebæk NE, Berthelsen JG, Müller J, Giwercman A, von der Maase H & Rørth M: Carcinoma in
situ testis. Ugeskr Læg 37:2154-2157, 1988.
49.
Skakkebæk NE, Berthelsen JG, von der Maase H, Rørth M & Osterlind A: Prevention of bilateral
testicular cancer: significance of detection and treatment of carcinoma in situ. Prog Clin Biol Res
303:779-789, 1989.
50.
Bentzen SM, Overgaard J, Thames HD, Overgaard M, Vejby Hansen P, von der Maase H & Meder
J: Clinical radiobiology of malignant melanoma. Radiother Oncol 16:169-182, 1989.
51.
Brincker H, Jakobsen A, Kjær M, von der Maase H & Rose C: Undervisningsprogram i
cancersygdomme. Ugeskr Læg 151:3265-3267, 1989.
52.
Iversen P, Bak M, Juul N, Laursen F, von der Maase H: Ultrasonically guided 125iodine seed
implantation with external radiation in management of localized prostatic carcinoma. Urology 34:181186, 1989.
53.
Negrier S, Philip T, Stoter G et al.: Interleukin-2 with or without LAK cells in metastatic renal cell
carcinoma. A report of a European multicenter study. Eur J Cancer Clin Oncol 25, suppl. 3:21-28,
1989.
54.
Jacobsen GK, Rørth M, Østerlind K, von der Maase H et al.: Histopathological features in stage I
non-seminomatous testicular germ cell tumours correlated to relapse. Acta Pathol Microbiol Immunol
Scand 98:377-382, 1990.
55.
Hansen SW, Berthelsen JG & von der Maase H: Long-term fertility and Leydig cell function in
patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J
Clin Oncol 8:1695-1698, 1990.
56.
Geertsen PF, Hermann GG, Claësson H, Kenneth S, Zeuthen J & von der Maase H: Interleukin-2
baseret immunterapi af kræftsygdomme. Ugeskr Læg 152:3513-3518, 1990.
57.
von der Maase H: Experimental drug-radiation interactions in critical normal tissues. In: Antitumor
drug-radiation interactions. Editors: Bridget T. Hill & Angela S. Bellamy, CRC, Press, Florida, pp.
191-205, 1990.
58.
von der Maase H: Extragonadale germinative tumorer (leder). Ugeskr Læg 152:2219-2220, 1990.
4
59.
Rørth M, Jacobsen GK, von der Maase H et al.: Surveillance alone versus radiotherapy after
orchiectomy for clinical stage I non-seminomatous testicular cancer. J Clin Oncol 9:1543-1548, 1991.
60.
Skakkebæk NE, Giwercman A, von der Maase H: Carcinoma-in-situ of the testis and its
management. In: Urological Oncology: Dilemmas and Developments. Editors: A.R. Alderson, R.T.D.
Oliver, I.W.F. Hanham, and H.J.G. Bloom, John Wiley & Sons Ltd., Chichester, pp. 283-288, 1991.
61.
Damgaard-Pedersen K & von der Maase H: Ultrasound and ultrasound guided biopsy in the
diagnosis of retroperitoneal metastases in testicular cancer. Correlation to CT and lymphography.
Acta Chir Scand Urol Nephrol, suppl. 137:139-144, 1991.
62.
Giwercman A, von der Maase H, Berthelsen JG et al.: Localized irradition of testes with carcinomain-situ: effect on Leydig cell function and eradication of malignant germ cells in 20 patients. J Clin
Endocrinol Metabol 73:596-603, 1991.
63.
von der Maase H: Diagnosis and management of carcinoma in situ of the testis. In: Testicular
cancer. Editor: Alan Horwich, Chapman and Hall, London, pp. 319-330, 1991.
64.
Hermann GG, Geertsen PF, von der Maase H & Zeuthen J: Interleukin-2 dose, monocytes and
CD25+ lymphocyte counts as predictors of clinical response to Interleukin-2 therapy in patients with
renal cell carcinoma. Cancer Immunol Immunother 34:111-114, 1991.
65.
von der Maase H, Geertsen PF, Thatcher N et al.: Recombinant Interleukin-2 in metastatic renal cell
carcinoma – a European multicentre phase-II study. Eur J Cancer 27:1583-1589, 1991.
66.
Hippe E, Jønsson V, von der Maase H et al.: Homeostatic response criteria for cancer therapy. Eur J
Cancer 27:1715-1716, 1991.
67.
Hermann GG, Geertsen PF, von der Maase H et al.: Recombinant Interleukin-2 and LAK cell
treatment of advanced bladder cancer: Clinical results and immunological effects. Cancer Res
52:726-733, 1992.
68.
Geertsen PF & von der Maase H: Cancer testis. Månedsskrift for Praktisk Lægegerning 70:165-171,
1992.
69.
Geertsen PF, Herman GG, von der Maase H, Steven K: Treatment of metastatic renal cell carcinoma
by continuous intravenous infusion of recombinant Interleukin-2 – a single center phase II study. J
Clin Oncol 10:753-759, 1992.
70.
Drzewiecki KT & von der Maase H: Malignt melanom i huden. Månedsskrift for Praktisk Lægegerning
70:735-740, 1992.
71.
Lundbeck F & von der Maase H: Blæretumorer: Forekomst, diagnostik og behandling. Månedsskrift
for Praktisk Lægegerning 70:447-454, 1992.
72.
Daugaard G, Rørth M, von der Maase H, Skakkebæk NE: Management of extragonadal germ cell
tumors and the significance of bilateral testicular biopsies. Ann Oncol 3:283-289, 1992.
5
73.
von der Maase H, Østerlind A, Drzewiecki KT et al.: Melanoma malignum cutis i Danmark. Ugeskr
Læg 154:1949-1943, 1992.
74.
Carl J, Christensen TB & von der Maase H: Cisplatinum dose dependent response in germ cell
cancer evaluated by tumour marker modelling. Acta Oncol 31:749-753, 1992.
75.
Geertsen PF, Sengeløv L, Larsen SK, von der Maase H: A phase II study of cisplatin plus
methotrexate with folinic acid rescue in metastatic or locally recurrent transitional cell carcinoma of
the urothelium. Eur J Cancer 3:347-350, 1993.
76.
von der Maase H: Forskningen og det kliniske arbejde. Ugeskr Læg 155:914-916, 1993.
77.
Giwercman A, von der Maase H, Skakkebæk NE: Epidemiological and clinical aspects of carcinoma
in situ of the testis. Eur Urol 23:104-114, 1993.
78.
von der Maase H: Clinical aspects of carcinoma in situ of the testis: Concluding remarks. Eur Urol
23:251-252, 1993.
79.
Sengeløv L, Kamby C & von der Maase H: Systematisk kemoterapi ved blærecancer. Ugeskr Læg
155:1363-1368, 1993.
80.
Palmer PA, Atzpodien J, Philip T, Negrier S, Kirschner H, von der Maase H, Geertsen P, Evers P,
Loriaux E, Oskam R, Roest G, Vinke J & Franks CR: A comparison of 2 modes of administration of
recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous
administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer biother
8:123-136, 1993.
81.
Giwercman A, von der Maase H, Rørth M & Skakkebæk NE: Semen quality in testicular tumour and
CIS in the contralateral testis. Lancet 341:384-385, 1993.
82.
Overgaard M, Bertelsen K, Dalmark M, Gadeberg CC, von der Maase H, Overgaard J & Sell A: A
randomised feasibility study evaluating the effect of radiotherapy alone or combined with 5fluorouracil in the treatment of locally recurrent or inoperable colorectal carcinoma. Acta Oncol
32:547-553, 1993.
83.
von der Maase H: Behandling af testis cancer. Medicus 7:3-7, 1993.
84.
von der Maase H, Specht L, Jacobsen GK, Jakobsen A, Madsen EL, Pedersen M, Rørth M &
Schultz H: Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer
29A:1931-1934, 1993.
85.
Jones M, Philip T, Palmer P, von der Maase H, Vinke J, Elson P, Franks CR & Selby P: The impact
of Interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother 8:275-288, 1993.
86.
von der Maase H: Complications of combined radiotherapy and chemotherapy. Semin Radiat Oncol
4:81-94, 1994.
87.
Sengeløv L, Kamby C, Schou G & von der Maase H: Prognostic factors and significance of
chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract.
Cancer 74:123-133, 1994.
6
88.
Giwercman A, von der Maase H, Rørth M & Skakkebæk NE: Current concepts of radiation treatment
of carcinoma-in-situ of the testis. World J Urol 12:125-130, 1994.
89.
Jacobsen GK, von der Maase H, Specht L, Jakobsen A, Madsen EL, Pedersen M, Rørth M &
Schultz H: Histopathological features in stage I seminoma treated with orchidectomy only. J Urol
Pathol 3:85-94, 1995.
90.
Lindegaard JC, Studstrup HN, Nielsen OS, von der Maase H: Behandling af peniscancer. Ugeskr
Læg 157:1660-1664, 1995.
91.
Sengeløv L, Nielsen OS, Kamby C & von der Maase H: Platinum analogue combination
chemotherapy: cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract
tumors. A phase II trial with evaluation of prognostic factors. Cancer 76:1797-1803, 1995.
92.
Lorentzen T, Sengeløv L, Nolsøe CP, Khattar SC, Karstrup S & von der Maase H: Ultrasonically
guided insertion of a peritoneogastric shunt in patients with malignant ascites. Acta Radiol 36:481484, 1995.
93.
Sengeløv L, Nielsen OS, Kamby C & von der Maase H: Systemic mitomycin-C as second line
treatment for metastatic urothelial cancer. Acta Oncol 34:978-979, 1995.
94.
Lindegaard JC, Nielsen OS, Lundbeck FA, Mamsen A, Studstrup HN & von der Maase: A
retrospective analysis of 82 cases of cancer of the penis. Br J Urol 77:883-890, 1996.
95.
Sengeløv L, Kamby C & von der Maase H: Pattern of metastases in relation to characteristics of
primary tumor and treatment in patients with disseminated urothelial carcinoma. J Urol 155:111-114,
1996.
96.
von der Maase H: Diagnosis and management of carcinoma in situ of the testis. In: Testicular
Cancer. Investigation and Management. Chapman and Hall, London. Editor: Horwich A, pp. 319-330,
1996.
97.
von der Maase H: Phase II study of gemcitabine and cisplatin in advanced metastatic bladder
cancer. A preliminary report. Recent Clinical Advances with Gemzar 3:47-51, 1996.
98.
Krarup T, Nielsen K, Wolf H et al.: Urinblæretumorer. Ugeskr Læg 159, suppl. 1:1-14, 1997.
99.
Sengeløv L, Klintorp S, Havsteen H, Kamby C, Hansen SL & von der Maase H: Treatment outcome
following radiotherapy in elderly patients with bladder cancer. Radiother Oncol 44:53-58, 1997.
100.
Andersen LJ, Sengeløv L, Kamby C & von der Maase H: Cisplatin, metotrexate and mitoxantrone in
patients with metastatic or advanced urothelial cancer. Acta Oncol 37:110-112, 1998.
101.
Christensen TB, Daugaard H, Geertsen PF & von der Maase H: Effect of chemotherapy on
carcinoma in situ of the testis. Ann Oncol 9:1-4, 1998.
102.
Geertsen PF, von der Maase H, Olsen NV, Fogh-Andersen N, Nielsen SL & Leyssacs PP: Renal
haemodynamics, sodium and water reabsorption during continuous intravenous infusion of
recombinant interleukin-2. Clin Sci 95:73-81, 1998.
7
103.
Iversen P, Rasmussen F, Mogensen P, Lundbeck F, Poulsen J, Rossen JU, Skaarup P, Brasso K,
Svanholm H & von der Maase H: Prostatacancer. Ugeskr Læg, suppl. 4:1-32, 1999.
104.
Christensen TB, Marqversen J, Engbaek F, Berger P, Bacher T & von der Maase H: Validation of
125I-HCG as a marker for elimination of hCG after in vivo injection in humans. Br J Cancer 80:15821587, 1999.
105.
Christensen TB, Engbaek F, Marqversen J, Nielsen SL, Kamby C & von der Maase H: 125I-HCG as
an elimination marker in the evaluation of hCG decline during chemotherapy in patients with
testicular cancer. Br J Cancer 80:1577-1581, 1999.
106.
Ehrnrooth E, von der Maase H, Sørensen BS, Poulsen JH & Horsman MR: The ability of hypoxia to
modify the gene expression of thymidylate synthase in tumour cells in vivo. Int J Radiat Oncol
75:885-891, 1999.
107.
Aboagye-Mathiesen G, Ebbesen P, von der Maase H & Celis JE: Interferon gamma regulates a
unique set of proteins in fresh human bladder transitional cell carcinomas. Electrophoresis 20:344348, 1999.
108.
Sengeløv L, von der Maase H, Kamby C, Jensen LI, Rasmussen F, Horn T, Nielsen SL & Steven K:
Assessment of patients with metastatic transitional cell carcinoma of the urinary tract. J Urol
162:343-346, 1999.
109.
Sengeløv L & von der Maase H: Radiotherapy in bladder cancer. Radiother Oncol 52:1-14, 1999.
110.
von der Maase H: Non-kirurgisk behandling af kræft ved årtusindskiftet. Ugeskr Læg 161:6157,
1999.
111.
von der Maase H & Høyer M: Ekstracerebral stereotaktisk strålebehandling. Et nyt
behandlingsprincip. Ugeskr Læg 161:2957, 1999.
112.
von der Maase H, Andersen L, Crinó L, Weinknecht S & Dogliotti L: Weekly gemcitabine and
cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II
clinical trial. Ann Oncol 10:1461-1465, 1999.
113.
Schmidt H, Geertsen PF, Fode K, Rytter C, Bastholt L & von der Maase H: Subcutaneous
Interleukin-2 and alfa-Interferon plus cisplatin with and without prophylactic Cimetidine in 87 patients
with metastatic malignant melanoma: A phase II study. Melanoma Res 10:66-77, 2000.
114.
Ehrnrooth E, Sørensen BS, Meldgaard P, Poulsen JH & von der Maase H: A new quantitative RT
PCR assay for thymidylate synthase mRNA in blood leukocytes applied to cancer patients and
healthy controls. Clin Chim Acta 290:129-144, 2000.
115.
Ehrnrooth E, Poulsen JH, Sørensen BS, Sørensen B & von der Maase H: Changes in thymidylate
synthase mRNA in blood leukocytes after bolus infusion of 5-fluorouracil. Acta Oncol 1:53-57, 2000.
116.
von der Maase H: Gemcitabine in locally advanced and/or metastatic bladder cancer. Crit Rev in
Oncology/haematology 34:175-184, 2000.
8
117.
von der Maase H: Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer.
Eur J Cancer 36:13-16, 2000.
118.
Sørensen BS, Schmidt H, von der Maase H, Straten PT & Nexø E: Quantification of melanoma cellspecific MART-1 mRNA in peripheral blood by a calibrated competitive reverse transcription-PCR.
Clin Chem 46:1923-1928, 2000.
119.
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P,
Knuth A, Stockamp K, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF,
Tomlin I, Visseren-Grul CM & Conte PF: Gemcitabine and cisplatin versus MVAC in advanced or
metastatic bladder cancer: Results of a large randomised multinational multicenter, phase III study. J
Clin Oncol 18:3068-3077, 2000.
120.
Primdahl H, von der Maase H, Christensen M, Wolf H & Ørntoft TF: Allelic deletions of cell growth
regulators during progression of bladder cancer. Cancer Res 60:6623-6629, 2000.
121.
Sengeløv L, Kamby C, Geertsen P, Andersen LJ & von der Maase H: Predictive factors of response
to cisplatin-based chemotherapy and the relation of response for survival in patients with metastatic
urothelial cancer. Cancer Chemother Pharmacol 46:357-364, 2000.
122.
Sengeløv L, Christensen M, von der Maase H, Horn T, Marcussen N, Kamby C & Ørntoft T: Loss of
heterozygosity at 1p, 8p, 10p, 13q, and 17p in advanced urothelial cancer and lack of relation to
chemotherapy response and outcome. Cancer Genet Cytogenet 123:109-113, 2000.
123.
von der Maase H & Hayden AM: Gemcitabine and Cisplatin for advanced, metastatic bladder cancer.
J Clin Oncol 19:1229-1231, 2001.
124.
von der Maase H: Do we have a new standard of treatment for patients with seminoma stage II and
stage IIB? Radiother Oncol 59:1-3, 2001.
125.
von der Maase H: Gemcitabine in advanced bladder cancer. Semin Oncol 28, suppl. 7:11-4, 2001.
126.
de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fossa SD, Cook P, De Prijck L,
Stenning S & Collette L: Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin
chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized
study of the European Organization for Research and Treatment of Cancer, Genitourinary Tract
Cancer Cooperation Group and the Medical Research Council. J Clin Oncol 19:1629-1640, 2001.
127.
Sengeløv L, Kamby C & von der Maase H: Metastatic urothelial cancer: evaluation of prognostic
factors and change in prognosis during the last twenty years. Eur Urol 39:634-642, 2001.
128.
von Eyben FE, Madsen FL, Blaabjerg O, Petersen PH, von der Maase H, Jacobsen GK & Rørth M:
Serum lactate dehydrogenase isoenzyme1 and relapse in patients with non-seminomatous testicular
germ cell tumors clinical stage I. Acta Oncol 40:536-540, 2001.
129.
von der Maase H: Gemcitabine-containing regimens in bladder cancer. A new standard of care.
Semin Oncol 28, suppl. 10:1-3, 2001.
9
130.
von der Maase H: Combined effect of radiotherapy and chemotherapy. In: The Oxford Textbook of
Oncology, University Press, Oxford. Editors: Souhami SL, Tannock I, Hohenberger P, Horiot J-C, pp.
490-509, 2001.
131.
Primdahl H, Wikman FP, von der Maase H, Zhou X-g, Wolf H & Ørntoft T: Allelic imbalances in
human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism
arrays. J Natl Cancer Inst 94:216-223, 2002.
132.
von Eyben FE, Madsen EL, Blaabjerg O, Petersen PH, Jacobsen GK, Specht L, Pedersen BN & von
der Maase H: Serum lactate dehydrogenase isoenzyme1 in patients with seminoma stage I followed
with surveillance. Acta Oncol 41:77-83, 2002.
133.
Donskov F, von der Maase H, Henriksson R, Stierner U, Wersäll P, Nellemann H, Hellstrand K,
Engman K & Naredi P: Outpatient treatment with subcutaneous histamine dihydrochloride in
combination with Interleukin-2 and Interferon-alpha in patients with metastatic renal cell carcinoma:
Results of an open, single-armed, multicenter phase II study. Ann Oncol 13:441-449, 2002.
134.
Ehrnrooth E, Zacharia R, Svendsen G, Jørgensen MM, Yishay M, Sørensen BS, Poulsen JH & von
der Maase H: Increased thymidylate synthase mRNA concentration in blood leukocytes following an
experimental stressor. Psychother Psychosom 71:97-103, 2002.
135.
von der Maase H: Current and future perspectives in advanced bladder cancer: is there a new
standard? Semin Oncol 29, suppl. 3:3-14, 2002.
136.
Petersen PM, Giwercman A, Daugaard G, Rørth M, Petersen JH, Skakkebæk NE, Hansen SW &
von der Maase H: Effect of graded testicular doses of radiotherapy in patients treated for carcinomain-situ in the testis. J Clin Oncol 20:1537-1543, 2002.
137.
Primdahl H, von der Maase H, Christensen M, Wolf H & Ørntoft TF: Allelic deletions of Rb and L-myc
in urine sediments from patients with bladder tumours or carcinoma in situ. Oncol Rep 9:551-555,
2002.
138.
Schmidt H, Sørensen BS, von der Maase H, Bang C, Agger R, Hokland M & Nexø E: Quantitative
RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic
melanoma. Melanom Res 12:585-592, 2002.
139.
Stadler WM, Hayden A, von der Maase H, Roychowdhury D, Dogliotti L, Seymour L, Kaufmann D &
Moore M: Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional
cell cancer. Urol Oncol 7:153-157, 2002.
140.
Primdahl H, von der Maase H, Sørensen FB, Wolf H & Ørntoft TF: Immunohistochemical study of the
expression of cell cycle regulating proteins at different stages of bladder cancer. J Cancer Res Clin
Oncol 128:295-301, 2002.
141.
Fuglsang J, Fokdal LU & von der Maase H: Tre episoder af trombose i vena jugularis interna. Ugeskr
Læg 164:3071-3072, 2002.
142.
Daugaard KG & von der Maase H: Cancer testis. Ugeskr Læg 164:3063-3067, 2002.
143.
von der Maase H & Steven K: Cancer vesicae urinariae. Ugeskr Læg 164:3052-3056, 2002.
10
144.
Drzewiecki KT & von der Maase H: Melanoma malignum cutis. Ugeskr Læg 164:3031-3035, 2002.
145.
Andersen MH, Schmidt H, Gehl J, von der Maase H & thor Straten P: Immuterapi af
cancersygdomme. Ugeskr Læg 164:3008-3016, 2002.
146.
von der Maase H: Onkologisk behandling. Ugeskr Læg 164:2999, 2002.
147.
von Eyben FE, Jacobsen GK, Specht L, Petersen PH, Madsen EL, Blaabjerg O, Rørth M & von der
Maase H: Serum lactate dehydrogenase isoenzyme1 in patients with testicular seminoma or nonseminoma stage I: Two nationwide Danish studies of surveillance. In: Germ Cell Tumours V,
Springer-Verlag, London. Editors: Harnden P, Joffe JK, Jones WG, pp. 55-56, 2002.
148.
Larsen LH & von der Maase H: Predictive factors for residual teratoma after chemotherapy for nonseminomatous germ cell tumours (NSGCT). In: Germ Cell Tumours V, Springer-Verlag, London.
Editors: Harnden P, Joffe JK, Jones WG, pp. 157-158, 2002.
149.
Larsen EH, Frimodt-Møller PC, Horn T, Dorph S & von der Maase H: Nyrecancer. Klaringsrapport nr.
7, www.ugeskriftet.dk, 2002.
150.
Colstrup H & von der Maase H: Nyrecancer – en ny klaringsrapport. Ugeskr Læg 164:5359, 2002.
151.
Schmidt H, Larsen S, Bastholt L, Fode K, Rytter C & von der Maase H: A phase II study of outpatient
subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with
metastatic melanoma. Ann Oncol 13:1919-1924, 2002.
152.
Sengeløv L, von der Maase H, Lundbeck F, Barlebo H, Colstrup H, Engelholm SA, Krarup T,
Madsen EL, Meyhoff HH, Mommsen S, Nielsen OS, Pedersen D, Steven K & Sørensen B:
Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder
tumours. Acta Oncol 41:447-456, 2002.
153.
Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowich M & von der Maase H:
Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J
Clin Oncol 15:4448-4452, 2002.
154.
Donskov F, Bennedsgaard KM, von der Maase H, Marcussen N, Fisker R, Jensen JJ, Naredi P &
Hokland M: Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal
cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response
and survival. Br J Cancer 87:194-201, 2002.
155.
von der Maase H & Tveter KJ: Cancer testis. In: Kirurgisk kompendium, Ny Nordisk Forlag Arnold
Busck, Copenhagen. Editors: Stadil F, Lund B and Nordling J, pp. 1463-1475, 2003.
156.
Fossa SD, de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Cook P, de Prijck L,
Stenning S, Aaronson NK, Bottomley A, Collette L; European Organization for Research and
Treatment of Cancer Genitourinary Group 30941; Medical Research Council Testicular Cancer
Study Group TE20: Quality of life in good prognosis patients with metastatic germ cell cancer: a
prospective study of the European Organization for Research and Treatment of Cancer
Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).
21:1107-1118, 2003.
11
157.
Donskov F & von der Maase H: Nefrektomi ved metastatisk renalcellecarcinom – en gammel myte i
ny forklædning? Ugeskr Læg 165:809-810, 2003.
158.
Zachariae R, Pedersen CG, Jensen AB, Ehrnrooth E, Rossen PR & von der Maase H: The
association of perceived physician communication style with patient satisfaction, distress, cancerrelated self-efficacy, and perceived control over the disease. Br J Cancer 88:658-665, 2003.
159.
von der Maase H: Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev
Anticancer Ther 3:11-19, 2003.
160.
Oosterhof ON, Roberts JT, de Reijke TM, Engelholm SA, Horenblas S, von der Maase H, Neymark
N, Debois M, Collette L, and members of the EORTC-GU Group: Strontium-89 chloride versus
palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study
of the European Organization for Research and Treatment of Cancer Genitourinary Group. Eur J
Urol 44:519-526, 2003.
161.
Agerbaek M, Alsner J, Marcussen N, Lundbeck F & von der Maase H: Retinoblastoma protein
expression is an independent predictor both radiation response and survival in muscle invasive
bladder cancer. Br J Cancer 89:298-304, 2003.
162.
Donskov F, Marcussen N, Hokland M, Fisker R, Madsen HH & von der Maase H: In vivo assessment
of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients
with metastatic renal cell carcinoma. Br J Cancer 90:626-631, 2004.
163.
Ladekarl M, Agger R, Fleischer CC, Hokland M, Hulgaard EF, Kirkin A, von der Maase H, Petersen
MS, Rytter C, Zeuthen J & Gundersen HJG: Detection of circulating tumor lysate-reactive CD4+ T
cells in melanoma patients. Cancer Immunol Immunother 53:560-566, 2004.
164.
Geertsen PF, Gore ME, Negrier S, Tourani JM & von der Maase H: Safety and efficacy of
subcutateous and continuous intravenous infusion of rIL-2 in patients with metastatic renal cell
carcinoma. Br J Cancer 90:1156-1162, 2004.
165.
Schmidt H, Sørensen BS, Nexø E & von der Maase H: S100beta protein in peripheral blood may
predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic
melanoma. Melanoma Res 14:211-215, 2004.
166.
Fokdal L, Honoré H, Høyer M, Meldgaard P, Fode K & von der Maase H: Impact of changes in
bladder and rectal filling volume on organ motion and dose distribution of the bladder for
radiotherapy of urinary bladder cancer. Int J Rad Oncol Biol Phys 59:436-444, 2004.
167.
von Eyben FE, Jacobsen GK, Rørth M & von der Maase H: Microinvasive germ cell tumour (MGCT)
adjacent to testicular germ cell tumours. Histophatology 44:547-554, 2004.
168.
Fokdal L, Høyer M, Meldgaard P & von der Maase H: Long-term bladder, colorectal, and sexual
functions after radical radiotherapy for urinary bladder cancer. Radiother Oncol 72:139-145, 2004.
169.
Robinson P, von der Maase H, Bhalla S et al.: Cost-utility analysis of the GC versus MVAC regimens
for the treatment of locally advanced or metastatic bladder cancer. Expert Rev Pharmacoeconomics
Outcomes Res 4:27-38, 2004.
12
170.
Donskov F, Bennedsgaard KM, Hokland M, Marcussen N, Fisker R, Madsen HH, Fode K & von der
Maase H: Leukocyte orchestration in blood and tumor tissue following interleukin-2 based
immunotherapy in metastatic renal cell carcinoma. Cancer Immunol Immunother 53:729-739, 2004.
171.
Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek
NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T,
Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I,
Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M, Derigs HG, Dieckmann KP, Flasshove M,
Garcia del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones
W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O,
Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger
H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der Maase H, Walz P, Weinknecht S,
Weissbach L, Winter E & Wittekind C: European consensus on diagnosis and treatment of germ cell
cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol
15:1377-1399, 2004.
172.
Donskov F, von der Maase H, Marcussen N, Hamilton-Dutoit S, Madsen HH, Jensen JJ & Hokland
M: Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based
immunotherapy: no in vivo effect of Fas ligand tumor counterattack. Clin Cancer Res 10:7911-7916,
2004.
173.
von der Maase H: Pemetrexed in transitional cell carcinoma of the urothelium. Seminars of Oncology
18, suppl. 8:48-50, 2004.
174.
Fokdal L, Høyer M & von der Maase H: Treatment outcome and prognostic variables for local control
and survival in patients receiving radical radiotherapy for urinary bladder cancer. Acta Oncol 43:74957, 2004.
175.
Koed K, Wiuf C, Christensen LL, Wiekman FP, Zieger K, Moller K, von der Maase H & Orntoft TF:
High-density single nucleotide polymorphism array defines novel stage and location-dependent
allelic imbalances in human bladder tumors. Cancer Res 65:34-45, 2005.
176.
Sengeløv L & von der Maase H: Kemoterapi som supplement til radikal behandling af patienter med
muskelinvasiv blærecancer. Ugeskr Læg 167:749-751, 2005.
177.
von der Maase H & Sengeløv L: Chemotherapy in locally advanced and metastatic bladder cancer.
Am J Cancer 4:1-13, 2005.
178.
Fokdal L, Honoré H, Høyer M & von der Maase H: Dose-volume histograms associated to long-term
colorectal functions in patients receiving pelvic radiotherapy. Radiother Oncol 74:203-210, 2005.
179.
Thind P, Bødker A, Dørfflinger T, Hermann G, Krarup T, Marcussen N, Møller K, Rasmussen F,
Sengeløv L & von der Maase H: Urinblæretumorer. Betænkning, 2005.
180.
Rosenberg JE, von der Maase H, Seigne JD, Mardiak J, Vaughn DJ, Moore M, Sahasrabudhe D,
Palmer PA, Perez-Ruizo JJ & Small EJ: A phase II trial of R115777, an oral farnesyl transferase
inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 103:2035-41,
2005.
13
181.
Aristides M, von der Maase H, Roberts T, Brown A, Kielhorn A & Bhalla S: Determining patient
preferences for improved chemotoxicity during treatment for advanced bladder cancer. Eur J Cancer
Care 14:141-142, 2005.
182.
von der Maase H, Sengeløv L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A
& Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin,
with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol 23:4602-4608, 2005.
183.
Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe K, de Wit R, Aass N, Graham
JD, Coleman R, Kirk SJ & Stenning SP: MRC TE19 collaborators and the EORTC 30982
collaborators: Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I
seminoma: a randomised trial. Lancet 366:293-300, 2005.
184.
Høyer M, Roed H, Sengeløv L, Traberg A, Ohlhuis L, Pedersen J, Nellemann H, Kiil Berthelsen A,
Eberholst F, Engelholm SA & von der Maase H: Phase-II study on stereotactic radiotherapy of locally
advanced pancreatic carcinoma. Radiother Oncol 76:48-53, 2005.
185.
von der Maase H: Do elderly patients with advanced urothelial carcinoma benefit from platinumbased chemotherapy? Nature Clin Pract Urol 2:318-319, 2005.
186.
Schmidt H, Sørensen BS, Fode K, Nexø E & von der Maase H: Tyrosinase messenger RNA in
peripheral blood is related to poor survival in patients with metastatic melanoma following Interleukin2 based immunotherapy. Melanoma Res 15:409-416, 2005.
187.
von der Maase H: Is a contralateral testicular biopsy in patients with unilateral germ cell testicular
cancer indicated as a routine procedure? Acta Oncol 44:523-525, 2005.
188.
Schmidt H, Bastholt L, Geertsen PF, Christensen IJ, Larsen S, Gehl J & von der Maase H: Elevated
neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with
metastatic melanoma: a prognostic model. Br J Cancer 93:273-278, 2005.
189.
Donskov F, Middleton M, Fode K, Meldgaard P, Mansoor W, Lawrence J, Thatcher N, Nellemann H
& von der Maase H: Two randomised phase II trials of subcutaneous interleukin-2 and histamine
dihydrochloride in patients with metastatic renal cell carcinoma. Br J Cancer 93:757-762, 2005.
190.
Safwat A, Schmidt H, Bastholt L, Fode K, Larsen S, Aggerholm N & von der Maase H: A phase II
trial combining low-dose total body irradiation and subcutaneous Interleukin-2 in metastatic
melanoma. Radiother Oncol 77:143-147, 2005.
191.
Schmidt H, Johansen JS, Sjoegran P, Christensen IB, Sorensen BS, Fode K, Larsen J & von der
Maase H: Serum YKL-40 predicts relapse-free and overall survival in patients with AJCC Stage I-II
melanoma. J Clin Oncol 24:798-804, 2006.
192.
Donskov F, Hokland M, Marcussen N, Torp Madsen HH & von der Maase H: Monocytes and
neutrophils as “bad guys” for the outcome of interleukin-2 with and without histamine in metastatic
renal cell carcinoma – results from a randomised phase II trial. Br J Cancer 30:218-226, 2006.
193.
Fokdal L, Høyer M & von der Maase H: Radical radiotherapy in urinary bladder cancer: Treatment
outcomes. Expert Rev Anticancer Ther 6:269-279, 2006.
14
194.
Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K & von der Maase H: Elevated serum level of
YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
Cancer 106:1130-1139, 2006.
195.
Bor P, Hindkjær J, Kølvraa S, Rossen P, von der Maase H, Jørgensen TM, Sørensen VT, Eiberg H
& Ingerslev JI: Screening for Y microdeletions in men with testicular cancer and undescended testis.
Assist Reprod Genet 23:41-45, 2006.
196.
Schmidt H, Sørensen BS, Sjoegren P, Christensen IJ, Fode K, Larsen J, Nexø E & von der Maase
H: Circulating tyronase and MART-1 messenger RNA does not independently predict relapse or
survival in patients with AJCC stage I-II melanoma. J Invest Dermatol 126:849-854, 2006.
197.
Duval L, Schmidt H, Kaltoft K, Fode K, Jensen JJ, Sørensen SM, Nishimura MI & von der Maase H:
Adoptive transfer of allogeneic, cytotoxic T-lymphocytes equipped with a HLA-A2 restricted MART-1
T-cell receptor: a phase I trial in metastatic melanoma. Clin Cancer Res 12:1229-1236, 2006.
198.
Hansen BD, Schmidt H, von der Maase H, Sjoegren P & Hokland M: Tumour-associated
macrophages are related to progression in patients with metastatic melanoma following interleukin-2
based immunotherapy. Acta Oncol 45:400-405, 2006.
199.
Donskov F & von der Maase H: Impact of immune parameters on long-term survival in metastatic
renal cell carcinoma. J Clin Oncol 24:1997-2005, 2006.
200.
von der Maase H: Dendritcellevaccination – et nyt behandlingstilbud til kræftpatienter? Ugeskr Læg
168:1413, 2006.
201.
Agerbaek M, Alsner J, Marcussen N, Lundbeck F & von der Maase H: Focal S100A4 protein
expression is an independent predictor of development of metastatic disease in cystectomized
bladder cancer patients. Eur Urol 50:777-785, 2006.
202.
Høyer M, Roed H, Hansen AT, Ohlhuis L, Petersen J, Nellemann H, Berthelsen AK, Grau C,
Engelholm SA & von der Maase H: Prospective study on stereotactic radiotherapy of limited-stage
non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 66, suppl. 4:128-135, 2006.
203.
Sternberg C, Donat SM, Bellmunt J, Millikan RE, Stadler W, de Mulder P, Sherif A, von der Maase H,
Tsukamoto T & Soloway M: Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant
chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. In: Bladder
Tumours, UICC, Editors: Soloway M, Carmach A, Khoury S, pp. 335-357, 2006.
204.
von Eyben FE, Jacobsen GK, Skotheim RI & von der Maase H: Precursor lesions in testis and
dysgenetic gonads. Hum Pathol 37:773-774, 2006.
205.
Roberts JT, von der Maase H, Sengeløv L, Conte PF, Dogliotti L, Oliver T, Moore MJ, Zimmermann
A & Arning M: Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and
methotrexate/vinblastine/doxorubicin in patients with locally advanced and metastatic bladder
cancer. Ann Oncol 17, suppl. 5:118-122, 2006.
15
206.
Høyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, Kiil Berthelsen A, Grau
C, Engelholm SA & von der Maase H: Phase II study on stereotactic body radiotherapy of colorectal
metastases. Acta Oncol 45:823-830, 2006.
207.
von der Maase H, Lehmann J, Gravis G, Joensuu H, Geertsen PF, Gough J, Chen G & Kania M: A
phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell
carcinoma of the urothelium. Ann Oncol 17:1533-1538, 2006.
208.
Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, de Mulder P, Sherif A, von der Maase
H, Tsukamoto T & Soloway MS: Chemotherapy for bladder cancer: treatment guidelines for
neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.
Urology 69, suppl. 1:62-79, 2007.
209.
Zachariae R, Paulsen K, Mehlsen M, Jensen AB, Johansson A & von der Maase H: Anticipatory
nausea: the role of individual differences related to sensory perception and autonomic reactivity. Ann
Beh Med 33:69-79, 2007.
210.
Als AB, Sengeløv L & von der Maase H: Long-term survival after gemcitabine and cisplatin in
patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary
treatment strategies. Eur Urol 52:478-486, 2007.
211.
von der Maase H: Editorial comment on: Weekly paclitaxel and carboplatin against advanced
transitional cell cancer after failure of a platinum-based regimen. Eur Urol 52:1122, 2007.
212.
Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont
AM, Keilholz U: Pretreatment levels of peripheral neutrophils and leukocytes as independent
predictors of overall survival in patients with American Joint Commission on Cancer Stage IV
Melanoma: results of the EORTC 18951 biotherapy trial. J Clin Oncol 25:1562,1569, 2007.
213.
Als AB, Dyrskjot L, von der Maase H, Koed K, Mansilla F, Toldbod HE, Jensen JL, Ulhoi BP,
Sengelov L, Jensen AB, Orntoft TF: EMMPRIN and survivin predict response and survival following
cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res
13:4407-4417, 2007.
214.
Hernberg M, Mattila P, Rissanen M, Hansson J, Aamdal S, Bastholt L, von der Maase H, Schmidt H,
Stierner U & Tarkkanen J: The prognostic role of blood lymphocyte subset distribution in patients
with resected high-risk primary or regionally metastatic melanoma. J Immunother 30:773-779, 2007.
215.
Zachariae R, Paulsen K, Mehlsen M, Jensen AB, Johansson A & von der Maase H: Chemotherapyinduced nausea, vomiting, and fatigue – the role of individual differences related to sensory
perception and automatic reactivity. Psychother Psychosom 76:376-384, 2007.
216.
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokomeyer C,
Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, de Mulder PH,
de Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K,
Flechon A, Fosså SD, Garcia Del Muro X, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S,
Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones
WG, Kesbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P,
Leiva Galvis O, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D,
Oosterhof GO, Paz Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R,
16
Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F,
Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter
E, Wood L & von der Maase H. European Consensus Conference on Diagnosis and Treatment of
Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus
Group (EGCCCG): Part I. Eur Urol 53:478-496, 2008.
217.
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokomeyer C,
Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, de Mulder PH,
de Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K,
Flechon A, Fosså SD, Garcia Del Muro X, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S,
Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones
WG, Kesbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P,
Leiva Galvis O, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D,
Oosterhof GO, Paz Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R,
Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F,
Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter
E, Wood L & von der Maase H. European Consensus Conference on Diagnosis and Treatment of
Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus
Group (EGCCCG): Part II. Eur Urol 53:497-513, 2008.
218.
Als AB, Sengeløv L & von der Maase H: Gemcitabine and cisplatin in locally advanced and
metastatic bladder cancer; 3- or 4-week schedule? Acta Oncol 47:110-119, 2008.
219.
Jensen HK, Nordsmark M, Donskov F, Marcussen N & von der Maase H: Immunohistochemical
expression of carbonic anhydrase IX assessed over time and during treatment in renal cell
carcinoma. BJU Int 101, suppl. 4:41-44, 2008.
220.
Ravaud A, Hawkins R, Gardner JP, von der Maase H, Zantl N, Harper P et al.: Lapatinib versus
hormone therapy in patients with advanced renal cell carcinoma: a randomised phase III clinical trial.
J Clin Oncol 26:2285-2291, 2008.
221.
Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J,
Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S
& von der Maase H: Phase III trial of vinflunine plus best supportive care compared with best
supportive care alone after a platinum-containing regimen in patients with advanced transitional cell
carcinoma of the urothelial tract. J Clin Oncol 27:4454-4461, 2009.
222.
Christensen S, Zachariae R, Jensen AB, Veath M, Moller S, Ravnbaek J & von der Maase H:
Prevalence and risk of depressive symptoms 3-4 months post-surgery in a nationwide cohort study
of Danish women treated for early stage breast cancer. Breast Cancer Res Treat 113:339-355, 2009.
223.
Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F & von der Maase H: Presence of
intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin
Oncol 27:4709-4717, 2009.
224.
Jensen HK, Donskov F, Nordsmark M, Marcussen N & von der Maase H: Increased intratumoral
FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell
carcinoma. Clin Cancer Res 15:1052-1058, 2009.
17
225.
Jessen C, Agerbaek M & von der Maase H: Predictive factors for response and prognostic factors for
long-term survival in consecutive, single institution patients with locally advanced and/or metastatic
transitional cell carcinoma following cisplatin-based chemotherapy. Acta Oncol 48:411-417, 2009.
226.
Køllgaard T, Duval L, Schmidt H, Kaltoft K, Seremet T, Andersen MH, von der Maase H, tor Straten
P, Hadrup SR: Longitudinal immune monitoring of patients receiving intratumoral injection of a
MART-1 T-cell receptor-transduced cell line (C-Cure 709). Cytotherapy 11:631-41, 2009.
227.
Pedersen AD, Rossen P, Mehlsen M, Pedersen CG, Zachariae R & von der Maase H: Long-term
cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc
15:296-301, 2009.
228.
Pedersen AF, Zachariae R, Jensen AB, Bovbjerg DH, Andersen O & von der Maase H:
Psychological stress predicts the risk of febrile episodes in cancer patients during chemotherapy.
Psychother Psychosom 78:258-260, 2009.
229.
Rossen PB, Pedersen AF, Zachariae R & von der Maase H: Health-related quality of life in long-term
survivors of testicular cancer. J Clin Oncol 27:5993-5999, 2009.
230.
Jeppesen AN, Jensen HK, Donskov F, Marcussen N & von der Maase H: Hyponatremia as a
prognostic and predictive factor in metastatic renal cell carcinoma. Br J Cancer 102:867-172, 2010.
231.
El-Hariry I, Powles T, Lau MR, Sternberg CN, Ravaud A, von der Maase H, Zantl N, Harper P,
Rolland F, Audhuy B, Barthel F, Machiels JP, Patel P, Kreuser ED & Hawkins RE: Amplification of
epidermal growth factor receptor gene in renal cell carcinoma. Eur J Cancer 46:859-862, 2010.
232.
Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H,
Vaughn DJ & Rosenberg JE: Prognostic factors in patients with advanced transitional cell carcinoma
of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol.
28:1850-1855, 2010.
233.
Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V; ESMO Guidelines
Working Group: Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 21 Suppl 5:140-146, 2010.
234.
Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V; ESMO Guidelines
Working Group: Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 21 Suppl 5:147-154, 2010.
235.
Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase
H; Nordic Melanoma Cooperative Group: Two different durations of adjuvant therapy with
intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a
randomised phase 3 trial. Lancet Oncol. 12:144-152, 2011.
236.
Bernstorf M, Balslev E, Lykkesfeldt AE, Kroman N, Harder E, von der Maase H, Jakobsen EH,
Grabau D, Ejlertsen B: Value of post-operative reassessment of estrogen receptor α expression
following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast
cancer. Breast Cancer Res Treat. 128:165-170, 2011.
18
237.
Brandberg Y, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, Hansson J: Healthrelated quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with
adjuvant intermediate-dose interferon alfa-2b. Eur J Cancer 48:2012-9, 2012.
238.
Rossen P, Pedersen AF, Zachariae R, von der Maase H: Sexuality and body image in long-term
survivors of testicular cancer. Eur J Cancer 48:571-8, 2012.
239.
Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A,
Chevreau C, Paz-Ares L, Laufman LR, Winquist E, Raghavan D, Marreaud S, Collette S, Sylvester
R, de Wit R: Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and
gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior
systematic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 30:1107-13, 2012.
240.
Poulsen HS, von der Maase H: MiRNA in glioblastomas - potentials and limitations. Ugeskr Laeger
174:628, 2012.
241.
Maughan BL, Agarwal N, Hussain SA, Boucher KM, von der Maase H, Kaufman DS, Lorusso V,
Moore MJ, Galsky MD, Sonpavde G: Pooled analysis of phase II trials evaluating weekly or
conventional cisplatin as first-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer
11:316-20, 2013.
242.
Bellmunt J, Fougeray R, Rosenberg JE, von der Maase H, Schutz FA, Salhi Y, Culine S, Choueiri
TK: Long-term survival results of a randomized phase III trials of vinflunine plus best supportive care
versus best supportive care alone in advanced urothelial carcinoma patients after failure in platinumbased chemotherapy. Ann Oncol. 24:1466-72, 2013.
243.
Branberg Y, Johansson H, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H,
Hansson J; Nordic Melanoma Cooperative Group: Role functioning before start of adjuvant treatment
was an independent prognostic factor for survival and time to failure. A report from the Nordic
adjuvant interferon trial for patients with high-risk melanoma. Acta Oncol. 52:1086-93, 2013.
244.
Carus A, Gurney H, Gebski V, Harnett P, Hui R, Kefford R, Wilcken N, Ladekarl M, von der Maase
H, Donskov F: Impact of baseline and nadir neutrophil index in non-small cell lung cancer and
ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. J
Transl Med 11:189, 2013.
245.
Mortensen MS, Lauritsen J, Gundgaard MG, Agerbæk M, Holm NV, Christensen IJ, von der Maase
H, Daugaard G: A nationwide cohort study of stage I seminoma patients followed on a surveillance
program. Eur Urol. 66:1172-8, 2014.
246.
Nordly M, Benthien KS, von der Maase H, Johansen C, Kruse M, Timm H, Vadstrup ES, Kurita GP,
von Heymann-Horan AB, Sjøgren P:The DOMUS study protocol: a randomized clinical trial of
accelerated transition from oncological treatment to specialized palliative care at home. BMC Palliat
Care13:44, 2014.
247.
Daugaard G, Gundgaard MG, Mortensen MS, Agerbæk M, Holm NV, Rørth M, von der Maase H,
Christensen IJ, Lauritsen J: Surveillance for stage I nonseminoma testicular cancer: outcomes and
long-term follow-up in a population-based cohort. J Clin Oncol. 32:3817-23, 2014.
19
248.
Mortensen MS, von der Maase H, Daugaard G: Reply to Jorge Aparicio, Pablo Maroto, Javier
Sastre, and José R. Germà's Letter to the Editor re: Mette Saksø Mortensen, Jakob Lauritsen, Maria
Gry Gundgaard, et al. A Nationwide Cohort Study of Stage I Seminoma Patients Followed on a
Surveillance Program. Eur Urol 66:1172-8, 2014. Urol Oncol. S1078-1439, 2015 [Epub ahead of
print]
249.
Kier MG, Lauritsen J, Almstrup K, Mortensen MS, Toft BG, Rajpert-De Meyts E, Skakkebaek NE,
Rørth M, von der Maase H, Agerbaek M, Holm NV, Andersen KK, Dalton SO, Johansen C,
Daugaard G: Screening for carcinoma in situ in the contralateral testicle in patients with testicular
cancer: a population-based study (DaTeCa 03 study). Ann Oncol. 2014 Dec 26. pii: mdu585. [Epub
ahead of print]
250.
Dohn LH, Illemann M, Høyer-Hansen G, Christensen IJ, Hostmark J, Litlekalsoy J, von der Maase H,
Pappot H, Laerum OD: Urokinase-type plasminogen activator receptor (uPAR) expression is
associated with T-stage and survival in urothelial carcinoma of the bladder. Urol Oncol. S1078-1439,
2015 [Epub ahead of print]
Antal PubMed indekserede artikler: 215
H-index: 43
January 2015
20